Results 161 to 170 of about 226,704 (244)
Aggressive prostate cancer is associated with pericyte dysfunction
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero +11 more
wiley +1 more source
La noblesse germanique et la réception des reliques romaines XVIIe-XVIIIe siècles
openaire +1 more source
Attention-Aware Graph Neural Network Modeling for AIS Reception Area Prediction. [PDF]
Renaud A, Iphar C, Napoli A.
europepmc +1 more source
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard +12 more
wiley +1 more source
What has been the impact of western governments' laws and policies on the mental health of asylum seekers and refugees? A systematic-narrative hybrid literature review. [PDF]
Amouri IE, Sabchev T.
europepmc +1 more source
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang +8 more
wiley +1 more source
Community as the key to socio-education: an analysis of challenges and practices in migratory contexts. [PDF]
Santoro M +4 more
europepmc +1 more source
Politique de remboursement des frais de déplacement, de représentation et de réception [PDF]
core
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard +5 more
wiley +1 more source

